Orthofix Medical, Inc. (OFIX)
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
$9.29-0.21%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
QuarterlyIQ Insights · OFIX
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Increase full-year 2026 net sales guidance to $845 million to $855 million, reflecting approximately 5% year-over-year pro forma constant currency growth.
Stated as a priority in 3 of last 3 quarters. Revenue guidance was reaffirmed near $850M to $860M in 2026-Q1 and increased slightly to $845M to $855M in 2026-Q2, reflecting about 5% pro forma constant currency growth year-over-year. The trajectory is delivering consistent growth with incremental upward revisions.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 51% of the time over the next year (vs 41% for the rest of the cohort, n=13363).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Orthofix is increasing its full-year 2026 guidance for net sales to $845 million to $855 million.”
“Net sales expected to range between $850 million to $860 million.”
“Company reaffirmed full-year 2026 net sales guidance of $850 million to $860 million.”
Increase full-year 2026 non-GAAP adjusted EBITDA guidance to $95 million to $98 million, reflecting margin expansion and operating discipline.
Stated as a priority in 3 of last 3 quarters. Non-GAAP adjusted EBITDA guidance was reaffirmed near $95M to $98M in 2026-Q1 and increased in 2026-Q2, reflecting operating discipline. Actual adjusted EBITDA was $20.1M in 2026-Q2, showing steady progress toward full-year targets. The trajectory is delivering margin expansion.
“Increasing full-year 2026 non-GAAP adjusted EBITDA guidance to $95 million to $98 million.”
“Non-GAAP adjusted EBITDA expected to be $95 million to $98 million.”
“Reaffirmed non-GAAP adjusted EBITDA guidance of $95 million to $98 million.”
Target positive free cash flow for full-year 2026, excluding impacts from potential legal settlements.
Stated as a priority in 3 of last 3 quarters. Management consistently expects positive free cash flow for full-year 2026 excluding legal settlements. However, actual cash from operations was negative $17.6M in 2026-Q1 and negative $17.6M in 2026-Q2, indicating limited progress toward positive free cash flow so far.
“Free cash flow expected to be positive for full-year 2026, excluding impact of any potential legal settlements.”
“Free cash flow expected to be positive for full-year 2026, excluding impact of any potential legal settlements.”
“Reaffirmed positive free cash flow expectation for full-year 2026.”
Realign Spine leadership to accelerate decision-making, sharpen accountability, and advance commercialization of key products including the 7D navigation platform.
Stated as a priority in 2 of last 3 quarters. Management realigned Spine leadership in early 2026 to improve commercial execution and innovation focus. While leadership changes were implemented, revenue growth in Spine-related segments showed modest increases, indicating progress but still early in execution.
“Orthofix announced strategic realignment of Spine leadership to accelerate profitable growth and sharpen execution.”
“Simplifying structure and placing decision-making closer to execution to move faster and scale opportunities.”
Focus on double-digit constant currency growth in Global Limb Reconstruction and Spine Fixation segments through commercial execution and product launches.
Newly stated in 2026-Q2. Management highlighted double-digit constant currency growth in Global Limb Reconstruction (11%) and Global Spine Fixation (3.5%) in Q2 2026. This represents early delivery on segment growth priorities with strong international performance and demand.
“Generated double-digit constant currency growth in Global Spine Fixation and Global Limb Reconstruction.”
Over the trailing year it converted 0.46x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity (low R² over the window).
7 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated stable grew net income 46% of the time over the next year (vs 53% for the rest of the cohort, n=3872).
Not investment advice. As of 2026-09-04.